Incyte

$82.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$3.65 (-4.27%) Today
+$0.46 (0.56%) As of 4:53 PM EDT after-hours

Why Robinhood?

You can buy or sell Incyte and other stocks, options, ETFs, and crypto commission-free!

About INCY

Incyte Corp. Common Stock, also called Incyte, is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Read More Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Employees
1,367
Headquarters
Wilmington, Delaware
Founded
1991
Market Cap
17.62B
Price-Earnings Ratio
57.92
Dividend Yield
0.00
Average Volume
1.02M
High Today
$85.82
Low Today
$81.61
Open Price
$85.56
Volume
1.20M
52 Week High
$89.30
52 Week Low
$57.00

Collections

INCY News

ReutersAug 16

UPDATE 2-FDA approves Celgene's bone marrow cancer treatment

92
ReutersJul 30

Edited Transcript of INCY earnings conference call or presentation 30-Jul-19 12:00pm GMT

8

INCY Earnings

-$0.43
-$0.04
$0.36
$0.75
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Oct 29, Pre-Market

More INCY News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.